Tag Archives: orphan drug

Biologics by McKesson Selected to Provide VONJO and PYRUKYND

Biologics by McKesson continues to solidify its leadership position a provider for limited and exclusive drugs in the specialty pharmacy market

Biologics Selected by Agios Pharmaceuticals as Exclusive Distributor of PYRUKYND®

PYRUKYND prescriptions are processed exclusively through Biologics by McKesson to give patients a seamless experience

IntegriChain’s Growth Drives Executive Promotions and Blue Fin Group Acquisition

IntegriChain acquisition of Blue Fin Group expands its commercialization capabilities and strengthens the company’s market access expertise

PANTHERx Rare selected by Xeris Pharmaceuticals as Exclusive Distributor of Recorlev

PANTHERx Rare was recently selected by Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Xeris Biopharma Holdings, Inc., as the exclusive U.S. pharmacy distribution partner for a new FDA-approved medication, Recorlev® (levoketoconazole).

Biologics by McKesson Starting the New Year With Momentum

Biologics by McKesson, selected as a specialty pharmacy distributor for three specialty drugs recently, is starting the new year with momentum

Aetna Launches New Network to Cover New Gene Therapies for Rare Diseases

Aetna recently announced an initiative to launch a designated network to cover new gene therapies for rare diseases. This follows an initiative by CVS Health in 2019 to provide self-insured employers with a stop-loss program with Aetna health plans and cover gene therapies

BioCryst’s Orladeyo Offers an Oral Treatment for HAE Patients

According to BioCryst Pharmaceuticals, the maker of Orladeyo, the medicine will be provided exclusively by specialty pharmacy Optime Care

BluePrint’s AYVAKIT and GAVRETO™ Selected Biologics and PantherRx Rare as Limited Specialty Pharmacies

Blueprint creates medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease